

# IT and IV Lentiviral Gene Therapy for X-ALD

NCT03727555

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Not Applicable
<b>Sponsor</b>	Shenzhen Geno-Immune Medical Institute
<b>Enrollment</b>	30 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- X-ALD patients e 1 year of age
- ALD diagnosis of the brain: evaluation of the VLCFA value in plasma
- Central imaging of the MRI to examine the damage on the CNS.
- Neurological function score (NFS) e 1
- Parent / guardian / patient signing informed consent
- ... and 1 more (see full listing online)

### Exclusion (5)

- HIV positive patients
- Stabilized condition after statins, Lorenzo's oil, or diet to reduce VLCFA levels
- Patients who are experiencing severe viral, bacterial or fungal infections, malignant tumors, heart abnormalities, liver dysfunction, or renal insufficiency
- Cannot perform an MRI
- Infection or dermatosis at pre-injection site

## Locations (1 total)

---

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China